Document Detail

Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
MedLine Citation:
PMID:  17159079     Owner:  NLM     Status:  MEDLINE    
The role of angiotensin type 2 receptor (AT(2)R) on vascular responses to angiotensin II in humans remains unclear. In this study we explored whether AT(2)R is expressed and functionally active on peripheral resistance arteries of hypertensive diabetic patients treated for 1 year with either the angiotensin receptor blocker valsartan or the beta-blocker atenolol. Twenty-six hypertensive type 2 diabetic patients treated with oral hypoglycemic and antihypertensive agents (not receiving angiotensin receptor blockers or beta-blockers) were randomly assigned to double-blind treatment for 1 year with valsartan or atenolol once daily added to their previous therapy in a clinical trial that we reported recently and compared with 10 normal subjects. Resistance arteries dissected from gluteal subcutaneous tissues were assessed on a pressurized myograph. Vasomotor response curves to angiotensin II (1 nmol/L to 1 micromol/L) were performed on norepinephrine precontracted vessels in the presence of valsartan (10 micromol/L) with or without the AT(2)R inhibitor PD123319 (1 micromol/L). AT(2)R expression was evaluated by confocal microscopy. After 1 year of treatment, systolic and diastolic blood pressure was controlled and comparable in the valsartan and atenolol groups. Angiotensin II evoked a significant vasodilatory response only on resistance arteries from patients treated with valsartan, effect blocked by PD123319. AT(2)R expression was 4-fold higher in small arteries of valsartan-treated patients. In conclusion, AT(2)Rs are upregulated and contribute to angiotensin II-induced vasodilation in resistance arteries of hypertensive diabetic patients treated with angiotensin type 1 receptor blockers and may mediate, in part, vascular actions of these drugs in high cardiovascular risk patients.
Carmine Savoia; Rhian M Touyz; Massimo Volpe; Ernesto L Schiffrin
Related Documents :
9609089 - Pressure overload induces cardiac hypertrophy in angiotensin ii type 1a receptor knocko...
9231829 - Induction of mitogen-activated protein kinase phosphatase-1 during acute hypertension.
6847819 - Role of vasopressin in blood pressure regulation during adrenal insufficiency.
596979 - Hypotensive action of an intra-nasally applied angiotensin ii-antagonist.
6362439 - Effects on intravascular pressures of vasopressin and angiotensin ii in dogs.
12877769 - Intravenous angiotensin ii does not affect dynamic baroreflex characteristics of the ne...
2955689 - Balloon dilation valvuloplasty of bioprosthetic valves in extracardiac conduits.
6612579 - Role of solute in the early restitution of blood volume after hemorrhage.
23392369 - Pretreatment with midazolam blunts the rise in intracranial pressure associated with ke...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-12-11
Journal Detail:
Title:  Hypertension     Volume:  49     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-01-19     Completed Date:  2007-02-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  341-6     Citation Subset:  IM    
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use*
Angiotensin II / pharmacology
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Antihypertensive Agents / therapeutic use
Arteries / drug effects,  physiopathology
Atenolol / therapeutic use*
Blood Pressure / drug effects
Diabetes Mellitus, Type 2 / complications*
Double-Blind Method
Drug Therapy, Combination
Hypertension / complications,  drug therapy,  physiopathology*
Middle Aged
Receptor, Angiotensin, Type 2 / metabolism*
Tetrazoles / therapeutic use*
Valine / analogs & derivatives*,  therapeutic use
Vascular Resistance*
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Receptor, Angiotensin, Type 2; 0/Tetrazoles; 11128-99-7/Angiotensin II; 137862-53-4/valsartan; 29122-68-7/Atenolol; 7004-03-7/Valine
Comment In:
Hypertension. 2007 Feb;49(2):270-1   [PMID:  17159080 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transposition of the great arteries.
Next Document:  Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide...